Oncotarget And The Rise of Thyroid Cancer Therapy Research

There are many articles today about Oncotarget, but most of these gauche articles are written by fledgling writers who probably don’t know anything scientific about the articles they are writing. Int his article, we will try to address this concern.

We will offer you only the articles that are written in such a concise manner that you won’t be able to ignore. You will also read in the article here a list of the information bits that are happening lately with Oncotarget. Shall we move on?

The Latest Study

One of the more prominent articles you can read today in ResearchGate is the fact that there’s now a proliferation of carcinogenic elements that can now be addressed with the help of various cancer therapies. In the article, there’s so much discussion about the role of FOX06 as a transcriptional factor in breast cancer. Visit Soundcloud to listen an audio podcast of Oncotarget.

Breast cancer today is one of the leading causes of death, and any research that can be found from Oncotarget that would push the study would mean a lot to the search for the cure. It’s also good to know that there are firms like ResearchGate that are successful enough in promoting what people need to know to remedy the issue.

In the ResearchGate article, there’s also a lot of information about MDA MB 468 AND hcc 38, which are all factors in understanding the growth of cancer in the body. There’s also a lot of overview of how the FOX06 will induce accumulation of cells in the G0/G1 phase cell cycle, but which excludes apoptosis.

The Eureka Alert Piece

Another thing you probably don’t know yet about Oncotarget is that there is right now an article from Eureka Alert website that shows how much promise there is for the people out there to find new therapies for thyroid cancer. Visit Oncotarget’s profile page at facebook.com

The research right now from Oncotarget seems to mirror all the advancements of research in other medical fields, and because of that, there’s already a lot of good things to expect from what will happen in Oncotarget.

That said, more of the research from thyroid cancer cure would most likely involve Oncotarget.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

The Innovative Career of Clay B. Siegall in the Bio-Technology Industry

Dr. Clay B. Siegall has been recognized for many years for his excellent knowledge of genetics and biotechnology. He has spent most his career life conducting research to discover ideal treatments for cancer. Siegall is also a co-founder of a top pharmaceutical enterprise that is called Seattle Genetics. He worked with other researchers to establish the facility in 1998 and has been acting as its CEO and chairperson. The company has a goal of making transformative scientific discoveries, doing detailed research, and developing drugs and therapies that can be used by cancer patients. The doctor has used his excellent knowledge of science to assist the company in creating various antibody-drug conjugates (ADCs). It has commercialized its products, and the first ADC that it sold was ADCETRIS®. The FDA licensed the product in 2011 and Seattle Genetics has managed to distribute it to over 65 countries where it is accepted. A partnership between the firm and Takeda Pharmaceutical Company has enabled ADCETRIS® to grow into a globally recognized brand. Researchers at the company have been striving to better the ADCs that it offers.


Seattle Genetics currently holds different strategic licenses that enable it to manufacture and distribute its drugs in several countries. Examples of the drugs that it has been developing include Pfizer, GlaxoSmithKline, Genentech, and AbbVie. The company has successfully generated $350 million from the medicines that it manufactures. The remarkable technology the Clay and his colleagues established at Seattle Genetics has been utilized in the development of more than 20 ADCs. The company has been working with other pharmaceutical corporations to manufacture its drugs externally. Seattle Genetics has developed excellent funding strategies under the management of Clay Siegall, and it has managed to secure a total of $1.2 billion.


Before the establishment of Seattle Genetics, Clay served as a researcher at various organizations. He started by working for the National Cancer Institute in 1988. Dr. Siegall was then offered a position at Bristol-Myers Squibb Pharmaceutical Research Institute. He has devoted his career to research work and has published more than 70 books that are used for professional and academic reference. Clay has also made various inventions, and he holds about 15 patents.